Billion

Gains

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">In a volatile day of trading, three major players in the automotive and biotech sectors are making headlines. Tesla (<a href="https://tokenist.com/investing/how-to-buy-stocks/" rel="noopener noreferrer nofollow" class="deco-link">NASDAQ: TSLA</a>), Rivian (<a href="https://tokenist.com/investing/how-to-buy-shares-online/" class="deco-link" rel="noopener noreferrer nofollow">NASDAQ: RIVN</a>), and Moderna (<a href="https://tokenist.com/investing/how-to-invest-in-stocks/" class="deco-link" rel="noopener noreferrer nofollow">NYSE: MRNA</a>) are each experiencing significant stock movements driven by analyst updates, strategic partnerships, and vaccine efficacy data. Here’s a closer look at the latest developments for these closely watched stocks.</p>
<h3 id="tesla-tsla-stock-gains-as-stifel-nicolaus-initiates-coverage-with-buy-rating-price-target-of-265">Tesla (TSLA) Stock Gains as Stifel Nicolaus Initiates Coverage with “Buy” Rating, Price Target of $265</h3>
<p>Tesla’s stock is rising, gaining 4.26% to reach $195.34 per share as of 11:58 AM EDT. The surge comes as Stifel Nicolaus <a href="https://www.investors.com/news/tesla-stock-buy-point-analyst-bullish/" target="_blank" aria-label="initiated coverage (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">initiated coverage</a> on the electric vehicle maker with a “buy” rating and a price target of $265.00, well above the current trading price. <br><br>This positive outlook contrasts with the overall analyst consensus, which maintains a “Hold” rating and a more conservative price target of $187.30.</p>
<p>Despite the day’s gains, Tesla’s year-to-date performance remains negative, down 21.46% and underperforming <a href="https://tokenist.com/investing/spx-vs-spy/" rel="noopener noreferrer nofollow" class="deco-link">the S&amp;P 500</a>. <br><br>The company recently reported quarterly earnings of $0.35 per share, meeting estimates, though revenue of $21.30 billion fell short of expectations. With a market capitalization of $622.404 billion and a <a href="https://tokenist.com/investing/p-e-ratio/" class="deco-link" rel="noopener noreferrer nofollow">P/E ratio</a> of 47.94, Tesla remains dominant in the EV market despite increasing competition.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="rivian-rivn-gets-a-5-billion-lifeline-from-volkswagen-stock-surges">Rivian (RIVN) Gets a $5 Billion Lifeline from Volkswagen, Stock Surges</h3>
<p>Rivian’s stock is experiencing a dramatic surge, up 26.80% to $15.16 per share, following news of a potential <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html" target="_blank" aria-label="$5 billion investment (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">$5 billion investment</a> from Volkswagen. <br><br>The proposed deal would involve forming an equally controlled joint venture to share EV architecture and software, potentially transforming Rivian’s market position and financial outlook.</p>
<p>Analysts are hailing the partnership as a “core game changer” for Rivian. The funding is expected to bolster the company’s cash reserves and support the development of new models, including the R2 SUVs and R3 crossovers. <br><br>However, some analysts caution that the funding could dilute Rivian’s share price. The news has propelled Rivian’s market capitalization to $15.094 billion, though the company still reports negative earnings, with an EPS of -$5.77.</p>
<h3 id="moderna-mrna-stock-faces-downward-pressure-after-release-of-efficacy-data-for-newly-approved-rsv-vaccine">Moderna (MRNA) Stock Faces Downward Pressure After Release of Efficacy Data for Newly Approved RSV Vaccine</h3>
<p>Moderna’s stock is facing downward pressure, declining 5.40% to $130.17 per share, following the <a href="https://seekingalpha.com/news/4119662-moderna-stock-dips-rsv-vaccine-efficacy-data?source=feed_sector_healthcare" target="_blank" aria-label="release of efficacy data (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">release of efficacy data</a> for its newly approved RSV vaccine, mRESVIA. <br><br>The latest data shows 50% vaccine efficacy against two or more lower respiratory tract disease symptoms, which some analysts consider to be on the lower end of expectations.</p>
<p>The FDA approved the vaccine last month for adults 60 and older and is now under review by the CDC’s Advisory Committee on Immunization Practices (ACIP). <br><br>The committee’s opinion will determine the vaccine’s market rollout. Moderna faces stiff competition from GSK and Pfizer, who already have approved RSV vaccines. Despite the day’s losses, Moderna’s year-to-date return remains positive at 30.89%, outperforming the S&amp;P 500.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/stocks-to-watch-today-tsla-rivn-and-moderna/">Stocks to Watch Today: TSLA, RIVN, and Moderna</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Stocks to Watch Today: TSLA, RIVN, and Moderna

Съдържание

Tokenist

Други статии, публикувани на 26.06.2024 г.

Shiba Inu Price Predictions: Mpeppe (MPEPE) Set To Dominate 2024 Market By 1000%

Binance’s Dubai unit wins VASP license

W3Expo — The Original In-Person Web3 Gaming Expo — Returns for Istanbul Blockchain Week 2024

Why Are Memecoins Declining?

BitDoge Meme Coin Launches Presale On Bitcoin Network

After a stunning victory over Portugal, the Georgian national team advanced to the quarterfinals ...

Присъединете се към нашия безплатен бюлетин за ежедневни крипто актуализации!